Influenza vaccine viruses and the development of seasonal vaccines: A Japanese perspective.

Cell culture-derived vaccine Seasonal influenza vaccine Test-negative design Vaccine effectiveness Vaccine productivity Vaccine virus

Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
12 07 2023
Historique:
received: 02 11 2022
revised: 17 02 2023
accepted: 18 05 2023
medline: 1 8 2023
pubmed: 9 6 2023
entrez: 8 6 2023
Statut: ppublish

Résumé

In Japan, the Ministry of Health, Labour and Welfare (MHLW) designates one specific virus strain for each component of the quadrivalent seasonal influenza vaccine, and four domestic manufacturers produce egg-based influenza vaccines with the same formulation (inactivated, split-virus) using uniform vaccine strains. Thus, discussions of the development of effective seasonal influenza vaccines so far has focused solely on the antigenic match between the vaccine strains and epidemic viruses. However, in 2017, the Japanese selection system of vaccine viruses demonstrated that even a candidate vaccine virus that is antigenically similar to the predicted circulating viruses is not necessarily suitable for vaccine production, given lower productivity of the vaccine. Taking this experience into account, the MHLW reformed the scheme of vaccine strain selection in 2018, and instructed the Vaccine Epidemiology Research Group created by the MHLW to probe how the virus strains for the seasonal influenza vaccine should be selected in Japan. In this context, a symposium, entitled "Issues of the Present Seasonal Influenza Vaccines and Future Prospects", was held as part of the 22nd Annual Meeting of the Japanese Society for Vaccinology in 2018, and subjects related to the influenza vaccine viruses were discussed among relevant administrators, manufacturers, and researchers. This report summarizes the presentations given at that symposium in order to convey the present scheme of vaccine virus selection, the evaluation of the resulting vaccines, and the efforts at new vaccine formulation in Japan. Notably, from March 2022, the MHLW has launched a discussion of the merits of the seasonal influenza vaccines produced by foreign manufacturers.

Identifiants

pubmed: 37291024
pii: S0264-410X(23)00640-0
doi: 10.1016/j.vaccine.2023.05.070
pii:
doi:

Substances chimiques

Influenza Vaccines 0
Vaccines, Combined 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4625-4631

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ‘Takao Hozawa is an employee of Denka Co., Ltd. in Tokyo, Japan. All other authors declare that they are free of competing interests.’

Auteurs

Hiroaki Kato (H)

Immunization Office, Health Service Division, Health Service Bureau, Ministry of Health, Labour and Welfare of Japan, 1-2-2, Kasumigaseki, Chiyoda-ku, Tokyo 100-8916, Japan.

Takao Hozawa (T)

Influenza Technical Committee, The Japan Association of Vaccine Industries, 2-14-4, Uchikanda, Chiyoda-ku, Tokyo 101-0047, Japan. Electronic address: takao-hozawa@denka.co.jp.

Wakaba Fukushima (W)

Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan; Research Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, 1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. Electronic address: wakaba@omu.ac.jp.

Eri Nobusawa (E)

Influenza Virus Research Center, National Institute of Infectious Diseases, Gakuen 4-7-1, Musashi-murayama, Tokyo 208-0011, Japan. Electronic address: nobusawa@nih.go.jp.

Yoshio Hirota (Y)

Clinical Epidemiology Research Center, SOUSEIKAI Medical Group (Medical Co. LTA), 3-6-1, Kashii-teriha, Higashi-ku, Fukuoka 813-0017, Japan. Electronic address: hiro8yoshi@lta-med.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH